Literature DB >> 27206721

Should the Frascati criteria for HIV-associated neurocognitive disorders be used in children?

David R Bearden1, Ana-Claire Meyer2.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27206721     DOI: 10.1212/WNL.0000000000002785

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  4 in total

1.  Operationalizing and evaluating the Frascati criteria for functional decline in diagnosing HIV-associated neurocognitive disorders in adults.

Authors:  Anastasia Matchanova; Steven Paul Woods; Victoria M Kordovski
Journal:  J Neurovirol       Date:  2019-11-19       Impact factor: 2.643

2.  Longitudinal Cognitive Outcomes in Children With HIV in Zambia: 2-Year Outcomes From the HIV-Associated Neurocognitive Disorders in Zambia (HANDZ) Study.

Authors:  Gauri Patil; Esau G Mbewe; Pelekelo P Kabundula; Hannah Smith; Sylvia Mwanza-Kabaghe; Alexandra Buda; Heather R Adams; Michael J Potchen; Milimo Mweemba; Brent A Johnson; Giovanni Schifitto; Handy Gelbard; Gretchen L Birbeck; David R Bearden
Journal:  J Acquir Immune Defic Syndr       Date:  2022-10-01       Impact factor: 3.771

3.  A neuropathologic diagnosis of Alzheimer's disease in an older adult with HIV-associated neurocognitive disorder.

Authors:  Joanna Hellmuth; Benedetta Milanini; Eliezer Masliah; Maria Carmela Tartaglia; Miranda B Dunlop; David J Moore; Shireen Javandel; Saskia DeVaughn; Victor Valcour
Journal:  Neurocase       Date:  2018-10-10       Impact factor: 0.881

4.  Socioeconomic Status and Cognitive Function in Children With HIV: Evidence From the HIV-Associated Neurocognitive Disorders in Zambia (HANDZ) Study.

Authors:  Esau G Mbewe; Pelekelo P Kabundula; Sylvia Mwanza-Kabaghe; Alexandra Buda; Heather R Adams; Colleen Schneider; Michael J Potchen; Milimo Mweemba; Manoj Mathews; J Anitha Menon; Bo Wang; Travis Baseler; Alex Paciorkowski; Gretchen L Birbeck; David R Bearden
Journal:  J Acquir Immune Defic Syndr       Date:  2022-01-01       Impact factor: 3.771

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.